Revised forecast
Fiscal year ending September 2026 · Full yearPrevious forecast published 6 November 2025The bar length represents the relative magnitude of change, based on the item that changed the most in this document. The percentage change shown by the dotted line is calculated from the two reported figures because the company did not provide the rate.
During the cumulative second quarter, sales of nuclear-related products for research institutions and products related to the restart of nuclear power plants increased, resulting in net sales and profit exceeding the initial forecasts.
| Item | Details |
|---|---|
| Net Sales | ¥5,800 million → ¥6,070 million（+4.7%） |
| Operating profit | ¥1,180 million → ¥1,280 million（+8.5%） |
| Ordinary income | ¥1,190 million → ¥1,290 million（+8.4%） |
| Profit attributable to owners of the parent | ¥833 million → ¥903 million（+8.4%） |
| Net income per share | 151.05 yen and sen → 163.74 yen and sen |
| Fiscal Period Covered | Fiscal year ending September 2026 |
| Period Covered | Full year |
| Publication date of previous forecast | 6 November 2025 |
| Previous-period results | Fiscal year ended September 2025: net sales ¥5,467 million, operating profit ¥1,165 million, ordinary profit ¥1,177 million, net income ¥794 million, net income per share ¥144.06 |
| Reason for the revision | During the cumulative second quarter, sales of nuclear-related products for research institutions and products related to the restart of nuclear power plants increased, resulting in net sales and profit exceeding the initial forecasts. |
| Dividend forecast revision | The interim dividend has been set at ¥26 per share, an increase of ¥1 from the most recent forecast of ¥25. The year-end dividend forecast has also been revised to ¥26 per share, an increase of ¥1 from the most recent forecast of ¥25, bringing the annual dividend forecast from ¥50 to ¥52. |
Items this document does not state (2)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.During the cumulative second quarter, sales of nuclear-related products for research institutions and products related to the restart of nuclear power plants increased, resulting in net sales and profit exceeding the initial forecasts. The dividend was increased based on recent business performance and the basic policy of paying stable and continuous dividends twice a year.